Incidence of herpes zoster in patients with inflammatory bowel disease
Copyright © 2024 Elsevier España, S.L.U. All rights reserved..
BACKGROUND: Herpes zoster (HZ) is a prevalent disease caused by the reactivation of the varicella-zoster virus (VZV) and associated with chronic morbidity, particularly with post-herpetic neuralgia (PHN). Inflammatory bowel disease (IBD) has been associated with an increased risk of HZ, mainly when immunosuppressive treatment (IMT) is used. However, studies assessing the risk of HZ in IBD are scarce.
AIMS: To evaluate the incidence rate and risk factors of HZ in IBD.
METHODS: Retrospective study in IBD patients with a positive VVZ serology from two referral hospitals from the area of Barcelona. Diagnosis of HZ and its clinical features were recorded.
RESULTS: A total of 398 IBD patients with a positive IgG-VVZ serology were identified. Fifty-eight percent of the patients received IMT (46.5% immunosuppressants monotherapy, 20.6% biologics monotherapy and, 32.7% combination therapy). After a median follow-up of 71 months (IQR 41.5-138.0), 17 (4.3%) patients developed HZ (cumulative incidence of 5.2 per 1000 person-year), 12 of them (70.6%) while receiving IMT. Median age at HZ episode was 38 years (IQR 27.5-52.5). Two (11%) developed PHN. Biological therapy was the only risk factor for developing HZ (OR 3.8 IC 95% 1.3-11.5; p=0.018).
CONCLUSIONS: HZ is quite prevalent in IBD, occurring at early ages and particularly among patients using IMT. NPH appears to occur in a notable proportion of cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - (2024) vom: 03. Feb. |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Incidencia de herpes zóster en pacientes con enfermedad inflamatoria intestinal: estudio observacional y retrospectivo en dos hospitales españoles de tercer nivel |
|---|
| Beteiligte Personen: |
Calm, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Enfermedad inflamatoria intestinal |
|---|
| Anmerkungen: |
Date Revised 25.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.gastrohep.2024.01.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36805439X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36805439X | ||
| 003 | DE-627 | ||
| 005 | 20240229155133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2024.01.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM36805439X | ||
| 035 | |a (NLM)38316174 | ||
| 035 | |a (PII)S0210-5705(24)00032-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Calm, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence of herpes zoster in patients with inflammatory bowel disease |
| 246 | 3 | 3 | |a Incidencia de herpes zóster en pacientes con enfermedad inflamatoria intestinal: estudio observacional y retrospectivo en dos hospitales españoles de tercer nivel |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND: Herpes zoster (HZ) is a prevalent disease caused by the reactivation of the varicella-zoster virus (VZV) and associated with chronic morbidity, particularly with post-herpetic neuralgia (PHN). Inflammatory bowel disease (IBD) has been associated with an increased risk of HZ, mainly when immunosuppressive treatment (IMT) is used. However, studies assessing the risk of HZ in IBD are scarce | ||
| 520 | |a AIMS: To evaluate the incidence rate and risk factors of HZ in IBD | ||
| 520 | |a METHODS: Retrospective study in IBD patients with a positive VVZ serology from two referral hospitals from the area of Barcelona. Diagnosis of HZ and its clinical features were recorded | ||
| 520 | |a RESULTS: A total of 398 IBD patients with a positive IgG-VVZ serology were identified. Fifty-eight percent of the patients received IMT (46.5% immunosuppressants monotherapy, 20.6% biologics monotherapy and, 32.7% combination therapy). After a median follow-up of 71 months (IQR 41.5-138.0), 17 (4.3%) patients developed HZ (cumulative incidence of 5.2 per 1000 person-year), 12 of them (70.6%) while receiving IMT. Median age at HZ episode was 38 years (IQR 27.5-52.5). Two (11%) developed PHN. Biological therapy was the only risk factor for developing HZ (OR 3.8 IC 95% 1.3-11.5; p=0.018) | ||
| 520 | |a CONCLUSIONS: HZ is quite prevalent in IBD, occurring at early ages and particularly among patients using IMT. NPH appears to occur in a notable proportion of cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Enfermedad inflamatoria intestinal | |
| 650 | 4 | |a Factores de riesgo | |
| 650 | 4 | |a Herpes zoster | |
| 650 | 4 | |a Herpes zóster | |
| 650 | 4 | |a Immunosuppression | |
| 650 | 4 | |a Inflammatory Bowel disease | |
| 650 | 4 | |a Inmunosupresión | |
| 650 | 4 | |a Risk factors | |
| 700 | 1 | |a Calafat, Margalida |e verfasserin |4 aut | |
| 700 | 1 | |a González-Muñoza, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Cañete, Fiorella |e verfasserin |4 aut | |
| 700 | 1 | |a Roig, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Mañosa, Míriam |e verfasserin |4 aut | |
| 700 | 1 | |a García-Planella, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Domènech, Eugeni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g (2024) vom: 03. Feb. |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:03 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2024.01.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 03 |c 02 | ||